✦ LIBER ✦

The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention: A TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38) Analysis

✍ Scribed by Michelle O'Donoghue; Elliott M. Antman; Eugene Braunwald; Sabina A. Murphy; P. Gabriel Steg; Ariel Finkelstein; William F. Penny; Viliam Fridrich; Carolyn H. McCabe; Marc S. Sabatine; Stephen D. Wiviott

Book ID: 119268433
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 480 KB
Volume: 54
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2009.05.025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early and Late Benefits of Prasugrel in

Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In Myocardial Infarction) Analysis

✍ Elliott M. Antman; Stephen D. Wiviott; Sabina A. Murphy; Juri Voitk; Yonathan Ha 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 287 KB

Evaluation of prasugrel compared with cl

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)

✍ Stephen D. Wiviott; Elliott M. Antman; C. Michael Gibson; Gilles Montalescot; Je 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 276 KB

Evaluation of prasugrel compared with cl

✍ Stephen D. Wiviott; Elliott M. Antman; C. Michael Gibson; Gilles Montalescot; Je 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 276 KB

Effect of prasugrel versus clopidogrel o

Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: A TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)–Thrombolysis in Myocardial Infarction (TIMI) 38 Substudy

✍ Yuri B. Pride; Stephen D. Wiviott; Jacqueline L. Buros; Cafer Zorkun; M. Umer Ta 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 177 KB

A Perspective on the Efficacy and Safety

A Perspective on the Efficacy and Safety of Intensive Antiplatelet Therapy in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

✍ Stephen D. Wiviott; Eugene Braunwald; Sabina A. Murphy; Elliott M. Antman 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 154 KB

American College of Cardiology/American

American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death: Observations From the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)

✍ Bonaca, M. P.; Wiviott, S. D.; Braunwald, E.; Murphy, S. A.; Ruff, C. T.; Antman 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 609 KB